GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » 3-Year EPS without NRI Growth Rate

PULM (Pulmatrix) 3-Year EPS without NRI Growth Rate : 36.30% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pulmatrix 3-Year EPS without NRI Growth Rate?

Pulmatrix's EPS without NRI for the three months ended in Dec. 2024 was $-0.53.

During the past 3 years, the average EPS without NRI Growth Rate was 36.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 47.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Pulmatrix was 66.60% per year. The lowest was -19.60% per year. And the median was 37.50% per year.


Competitive Comparison of Pulmatrix's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Pulmatrix's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmatrix's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Pulmatrix's 3-Year EPS without NRI Growth Rate falls into.


;
;

Pulmatrix 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Pulmatrix  (NAS:PULM) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Pulmatrix 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Pulmatrix's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmatrix Business Description

Industry
Traded in Other Exchanges
Address
945 Concord Street, Suite 1217, Framingham, MA, USA, 01701
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Executives
Peter Ludlum officer: Interim CFO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski officer: Chief Medical Officer C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan director C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore director C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert officer: Vice President, Finance 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen other: Former 10% owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint 10 percent owner 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210